Although CMS classification appears deceiving for biomarker development, ongoing trials focusing on different compounds (TGF-β, Tregs, MDSCs...) of the immune suppressive TME enriched in CMS4 CRC are still ongoing. This evidence concerns the gene TGFB1 and colorectal carcinoma.